This presentation contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding profitability, growth in revenue, the commercial potential of our products, and objectives of the company, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," ...

Continued Strong Revenue Growth Translated Into Significant Profit Growth Q4 2019 Financial Performance vs. Q4 2018 Business Highlights MACI full-year revenue growth of 35%, Epicel full- Vericel Q4 2019 Financial Results – February 25, 2020 3 +26% +66 bps +$5.1 million Total Revenue Growth Gross Margin Expansion Adjusted EBITDA Improvement VERICEL Q4 2019 RESULTS FEBRUARY 25, 2020 Safe Harbor This presentation contains forward-looking statements, including, without limitation, statements regarding full-year ...

A New Approach to Interstitial Lung Disease J.P. Morgan Healthcare Conference Sanjay S. Shukla, M.D., M.S., President and CEO January 16, 2025 Forward Looking Statements The following slides and any accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "f ...

CrowdStrike Investor Briefing September 2024 Safe Harbor This presentation includes express and implied "forward-looking statements", including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts, and in some cases, can be identified by terms such as "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict ...

Financial Data and Key Metrics Changes - For fiscal year 2025, the company reported total revenue of $70.2 million, a slight decline from $72.5 million in fiscal year 2024, primarily due to the exit from the Middle East business [12] - Core adjusted EBITDA reached $7.4 million, an increase of 365% from $1.6 million in the previous year, exceeding guidance of $6 million to $7 million [4][15] - The company ended the year with $2.8 million in cash and $1.1 million in long-term debt, providing flexibility for ongoing initiatives [15] Business Line Data and Key Metrics Changes - North America revenue grew 15% year over year from $57 million to $65.5 million, highlighting strong momentum in core markets [7][12] - The company has shifted focus to private equity-backed companies and exited lower-value, non-core geographies, which has strengthened its business model [5][6] Market Data and Key Metrics Changes - North America now represents over 93.3% of the company's revenue base, indicating a significant concentration in this market [6] - The company is seeing increased adoption of large-scale digital transformation initiatives among clients, reflecting a growing demand for its services [6][17] Company Strategy and Development Direction - The company has made intentional decisions to sharpen its strategy by focusing on core business areas and exiting non-core markets [5] - A new AI-centered global capability center framework has been launched, integrating intelligent automation and data-driven decision systems [10][11] - The company plans to continue hiring key personnel with relationships in the private equity industry to expand its pipeline and network [6][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in fiscal year 2026, projecting revenue between $74 million and $80 million and adjusted EBITDA between $6 million and $8 million [16][17] - The company is experiencing strong traction with clients, with existing clients deepening their partnerships and an expanding private equity network [17][18] Other Important Information - The restructuring process is complete, and stock-based compensation is expected to be significantly lower moving forward [13][15] - Fiscal year 2025 will be the last year to report core adjusted EBITDA as a separate metric, transitioning to adjusted EBITDA and GAAP measures [15] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session.

Financial Data and Key Metrics Changes - For fiscal year 2025, the company reported total revenue of $70.2 million, a decrease from $72.5 million in fiscal year 2024, primarily due to the exit from the Middle East business [11] - Core adjusted EBITDA reached $7.4 million, an increase of 365% from $1.6 million in the previous year, exceeding guidance [14] - The company ended the year with $2.8 million in cash and $1.1 million in long-term debt, providing flexibility for ongoing initiatives [14] Business Line Data and Key Metrics Changes - North America revenue grew 15% year over year from $57 million to $65.5 million, highlighting strong momentum in core markets [11][7] - The company has shifted focus to private equity-backed companies, enhancing its global capability center (GCC) model, which is now a preferred method for scalable capabilities in technology and operations [6][7] Market Data and Key Metrics Changes - North America now represents over 93.3% of the company's revenue base, indicating a significant concentration in this market [6] - The company is experiencing high client retention and increased adoption of large-scale digital transformation initiatives [6] Company Strategy and Development Direction - The company has exited lower-value, non-core geographies, specifically the Middle East consulting market, and has completed associated write-offs [5] - A new AI-centered GCC framework has been launched, integrating intelligent automation and data-driven decision systems to enhance client capabilities [9][10] - The company plans to continue hiring key personnel with relationships in the private equity industry to expand its pipeline and network [6] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in fiscal year 2026, projecting revenue between $74 million and $80 million and adjusted EBITDA between $6 million and $8 million [15][16] - The company is seeing strong traction with clients, with existing clients deepening partnerships and an expanding private equity network [16] - The cost structure is now lean, and AI-led transformation is gaining pace, indicating a positive outlook for future performance [17] Other Important Information - The restructuring process is complete, and stock-based compensation is expected to be significantly lower moving forward [12] - Fiscal year 2025 will be the last year to report core adjusted EBITDA as a separate metric, transitioning to adjusted EBITDA and GAAP measures [14] Q&A Session Summary - No specific questions or answers were provided in the content, indicating that the call concluded without a Q&A segment [19]

ZENVIA New Strategic Cycle 1Q 2025 Earnings Presentation Key Key Key Shay Chor Financial CFO Highlights Q1: Strong top-line growth and G&A efficiencies did not offset margin pressure 43 43 56.4% 53.7% 30.0% 40.0% 50.0% 60.0% 70.0% 80.0% 0.0 20.0 40.0 Q1 2024 Q1 2025 23 31 17% 14% 0 0% 10 20 30 Q1 2024 Q1 2025 24 20 0 20 40 Q1 2024 Q1 2025 94 74 44.0% 25.1% 10.0% 30.0% 50.0% 70.0% 0.0 50.0 100.0 Q1 2024 Q1 2025 213 296 Q1 2024 Q1 2025 Net Revenues (BRL MM) G&A Expenses and G&A-to-Revenues (BRL MM & %) EBITDA ...

Jefferies Global Life Sciences Conference Ingmar Bruns, M.D., CMO June 2025 Nasdaq: ZNTL Forward Looking Statements and Disclaimer Zentalis Pharmaceuticals, Inc. ("we," "us," "our," "Zentalis" or the "Company") cautions that this presentation (including oral commentary that accompanies this presentation) contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical ...

Company Overview - Albany International's market capitalization is $2 billion[13] - The company's 2024 revenue reached $1.231 billion[13] - Adjusted EBITDA for 2024 was $232 million[13] - The company's net debt in 2024 was $203 million[13] Machine Clothing (MC) Segment - The MC segment holds approximately 37% of the global paper machine clothing market share[63, 65] - Machine Clothing adjusted EBITDA margin is approximately 37% including Heimbach acquisition[83] - The Heimbach Group acquisition broadens the manufacturing footprint and enhances the sales and service network[81] Albany Engineered Composites (AEC) Segment - The AEC segment is focused on technology differentiation and maximizing customer solutions[101] - The company is investing in next-generation technologies for future growth in the AEC segment[97] Financial Performance & Strategy - The company's strategy for continued growth includes serving vital industries and solid execution[9] - The company's capital deployment is primarily focused on organic growth[37]

Company Overview - ESSA Pharma is focused on developing novel therapies for prostate and other androgen-driven cancers[7] - The company's lead candidate, EPI-7386, is a first-in-class oral, small molecule androgen receptor N-terminal domain inhibitor ("Aniten")[9, 28] - As of March 31, 2023, ESSA had $157 million in cash and short-term deposits, providing a runway through 2025[9, 69] EPI-7386 Monotherapy Development - Phase 1a study showed EPI-7386 was safe and well-tolerated, with tumor volume decreases observed in some patients[38] - ctDNA declines were observed in patients with AR mutations, amplifications, and truncations, suggesting activity against these tumors[38] - Phase 1b expansion study is underway to verify the recommended Phase 2 dose and gain further insight into EPI-7386's biological activity[40, 41] EPI-7386 Combination Therapy Development - ESSA is collaborating with multiple companies to evaluate EPI-7386 in combination with second-generation antiandrogens like enzalutamide, apalutamide, and darolutamide[49] - Initial data from the Phase 1/2 EPI-7386 + enzalutamide combination study showed rapid, deep, and durable PSA reductions[58] - In the combination study, 5 out of 6 patients achieved a PSA90, and 4 out of 6 patients achieved a PSA90 in 90 days and ultimately achieved a PSA < 02 ng/mL[58] Market and Opportunity - Prostate cancer is the 2nd most common cause of male cancer deaths, with an estimated 268,000 new cases and 34,500 deaths in 2022 in America[19] - Global sales of leading antiandrogens generated over $86 billion in 2021[19]